1.What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.
Yusuke KAWAMURA ; Kenji IKEDA ; Taito FUKUSHIMA ; Yuya SEKO ; Tasuku HARA ; Hitomi SEZAKI ; Tetsuya HOSAKA ; Norio AKUTA ; Masahiro KOBAYASHI ; Satoshi SAITOH ; Fumitaka SUZUKI ; Yoshiyuki SUZUKI ; Yasuji ARASE ; Hiromitsu KUMADA
Gut and Liver 2013;7(5):576-584
BACKGROUND/AIMS: The aim of this study was to determine the pharmacodynamics of cisplatin following three different treatment procedures for intrahepatic arterial infusion therapy for hepatocellular carcinoma (HCC). METHODS: We divided 13 HCC patients into the following three groups: group A, lone injection of cisplatin (n=3); group B, combined injection of cisplatin and lipiodol, with embolization using small gelatin cubes (GCs) (n=5); and group C, injection of suspended lipiodol with cisplatin powder, with embolization using small GCs (n=5). In each group, the free cisplatin concentration in the hepatic vein was measured at 0, 5, 10, and 30 minutes. RESULTS: The mean free cisplatin concentrations were as follows. For group A, the mean was 48.58 microg/mL at 0 minute, 7.31 microg/mL at 5 minutes, 5.70 microg/mL at 10 minutes, and 7.15 microg/mL at 30 minutes. For the same time points, for group B, the concentrations were 8.66, 4.23, 3.22, and 1.65 microg/mL, respectively, and for group C, the concentrations were 4.81, 2.61, 2.52, and 1.75 microg/mL, respectively. The mean area under the curve (AUC)0-infinity for the free cisplatin concentration was 7.80 in group A, 2.48 in group B, and 2.27 in group C. The AUC0-infinity for the free cisplatin concentration gradually decreased, from group A to group C. CONCLUSIONS: These results indicate that the combination of lipiodol and small GCs may be useful for delaying cisplatin drainage from the liver.
Carcinoma, Hepatocellular
;
Cisplatin
;
Drainage
;
Drug Delivery Systems
;
Ethiodized Oil
;
Gelatin
;
Hepatic Veins
;
Humans
;
Liver
;
Pilot Projects
2.Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
Norio AKUTA ; Yusuke KAWAMURA ; Yasuji ARASE ; Fumitaka SUZUKI ; Hitomi SEZAKI ; Tetsuya HOSAKA ; Masahiro KOBAYASHI ; Mariko KOBAYASHI ; Satoshi SAITOH ; Yoshiyuki SUZUKI ; Kenji IKEDA ; Hiromitsu KUMADA
Gut and Liver 2016;10(3):437-445
BACKGROUND/AIMS: It is important to determine the noninvasive parameters of histological features in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the value of genetic variations as surrogate markers of histological features. METHODS: The parameters that affected the histological features of NAFLD were investigated in 211 Japanese patients with biopsy-proven NAFLD. The relationships between genetic variations in PNPLA3 rs738409 or TM6SF2 rs58542926 and histological features were analyzed. Furthermore, the impact of genetic variations that affected the pathological criteria for the diagnosis of nonalcoholic steatohepatitis (NASH) (Matteoni classification and NAFLD activity score) was evaluated. RESULTS: The fibrosis stage of PNPLA3 GG was significantly more progressive than that of CG by multiple comparisons. Multivariate analysis identified PNPLA3 genotypes as predictors of fibrosis of stage 2 or more, but the impact tended to decrease at stage 3 or greater. There were no significant differences among the histological features of the three genotypes of TM6SF2. PNPLA3 genotypes partly affected the definition of NASH by the NAFLD activity score, but TM6SF2 genotypes did not affect the definition of NASH. CONCLUSIONS: In Japanese patients with biopsy-proven NAFLD, PNPLA3 genotypes may partly affect histological features, including stage of fibrosis, but the TM6SF2 genotype does not affect histological features.
Asian Continental Ancestry Group
;
Biological Markers
;
Classification
;
Diagnosis
;
Fatty Liver*
;
Fibrosis
;
Genetic Variation*
;
Genotype
;
Humans
;
Japan*
;
Multivariate Analysis
3.Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases.
Norihiro IMAI ; Kenji IKEDA ; Yuya SEKO ; Yusuke KAWAMURA ; Hitomi SEZAKI ; Tetsuya HOSAKA ; Norio AKUTA ; Masahiro KOBAYASHI ; Satoshi SAITOH ; Fumitaka SUZUKI ; Yoshiyuki SUZUKI ; Yasuji ARASE ; Hiromitsu KUMADA
Gut and Liver 2013;7(2):246-251
Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. In a phase II study, the plasma concentration of total platinum in patients who received miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. All cases were male, ages 72, 84, and 83 years, and had serum creatinine levels of 2.3, 1.6, and 1.9 mg/dL, respectively. Their estimated glomerular filtration rates were 21.9, 20.3, and 22.2 mL/min, respectively. All cases were treated for unresectable HCC with transcatheter arterial chemotherapy with miriplatin. No serious adverse events were observed, and serum creatinine levels did not elevate, even in the patient who experienced renal failure caused by cisplatin administration. These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure.
Carcinoma, Hepatocellular
;
Cisplatin
;
Creatinine
;
Glomerular Filtration Rate
;
Humans
;
Kidney Failure, Chronic
;
Male
;
Organoplatinum Compounds
;
Plasma
;
Platinum
;
Renal Insufficiency